Strategy & Commercialization (2)

Challenge An international oncology drug development company is developing a bispecific product, currently in preclinical development. As an initial evaluation, our client wanted to understand the...

Challenge A radiopharmaceuticals CDMO with activities in a range of therapeutic and diagnostic compounds including development-stage and commercial products asked Alacrita to assess the landscape and...

Challenge A group of healthcare investors with a long track record in the industry, but no biotechnology or research background, were interested in licensing a university project aimed at bladder...

Challenge: A biotech company developing immunomodulatory therapies asked Alacrita to assess the possible applications of its lead product, particularly in the context of improving the efficacy of...

Challenge On behalf of an established Alacrita client, a publicly traded clinical stage biotechnology company with a cell therapy platform technology, we assessed the potential of a novel...

Challenge A clinical-stage biotech company had an ongoing Phase 1 program exploring a combination therapy in multiple cancer types. The company wished to validate the addition of cholangiocarcinoma...

Challenge A UK-based oncology drug development company sought to understand the potential value of a small molecule product in metastatic breast cancer (MBC). Alacrita was commissioned to produce an...

Challenge A clinical stage microbiome company developing a microbiome therapeutic for the treatment of recurrent C. Difficile infection (rCDI) was looking to identify promising opportunities for new...

Challenge An early-stage, venture-backed, private biotechnology company developing a novel multi-gene therapy approach to addressing chronic, age-related diseases requested an opportunity mapping...

Challenge: A company with a microbiome-conditioning product was seeking the optimum strategic positioning to enable a trade sale to a major company. Unusually for a venture in this field, the company...

Challenge: A VC investor considering funding a radiopharmaceutical company requested an analysis of the therapeutic radiopharmaceutical landscape, to help them evaluate the investment. The purpose of...

Challenge: Our client was a clinical-stage biotech in the process of early stage planning for the launch of its first drug, a small molecule treatment for a rare endocrine disorder. However, the...